Waddell & Associates LLC Sells 931 Shares of Eli Lilly and Company (NYSE:LLY)

Waddell & Associates LLC reduced its position in Eli Lilly and Company (NYSE:LLYFree Report) by 14.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,700 shares of the company’s stock after selling 931 shares during the period. Eli Lilly and Company makes up 0.4% of Waddell & Associates LLC’s investment portfolio, making the stock its 24th largest holding. Waddell & Associates LLC’s holdings in Eli Lilly and Company were worth $3,290,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Lipe & Dalton purchased a new stake in Eli Lilly and Company in the 4th quarter valued at $26,000. Tidemark LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at $29,000. Optiver Holding B.V. purchased a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at $36,000. Frank Rimerman Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at $37,000. Finally, St. Johns Investment Management Company LLC increased its position in shares of Eli Lilly and Company by 123.3% during the 4th quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock valued at $39,000 after purchasing an additional 37 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Up 0.7 %

Shares of NYSE LLY opened at $856.00 on Monday. Eli Lilly and Company has a 12 month low of $434.34 and a 12 month high of $856.81. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The firm has a market capitalization of $813.55 billion, a price-to-earnings ratio of 125.18, a PEG ratio of 1.85 and a beta of 0.36. The business has a 50-day moving average of $775.80 and a 200-day moving average of $709.53.

Eli Lilly and Company (NYSE:LLYGet Free Report) last issued its quarterly earnings data on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. Eli Lilly and Company’s revenue was up 26.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.62 earnings per share. Sell-side analysts expect that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Thursday, May 16th will be given a $1.30 dividend. The ex-dividend date of this dividend is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.61%. Eli Lilly and Company’s payout ratio is 76.58%.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 target price (up from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday, April 30th. JPMorgan Chase & Co. raised their target price on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. Morgan Stanley increased their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Argus increased their price target on Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research note on Tuesday, May 14th. Finally, Truist Financial increased their price target on Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $787.53.

Get Our Latest Research Report on LLY

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 20,383 shares of the business’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $836.32, for a total value of $17,046,710.56. Following the completion of the sale, the insider now owns 98,188,427 shares in the company, valued at approximately $82,116,945,268.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 20,383 shares of the business’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $836.32, for a total value of $17,046,710.56. Following the completion of the sale, the insider now owns 98,188,427 shares in the company, valued at $82,116,945,268.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Johna Norton sold 7,056 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total value of $5,781,545.28. Following the completion of the sale, the executive vice president now owns 25,428 shares of the company’s stock, valued at approximately $20,835,194.64. The disclosure for this sale can be found here. Insiders sold 337,804 shares of company stock worth $278,236,284 in the last quarter. 0.13% of the stock is owned by insiders.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

See Also

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.